


**Product Name** : EOS301984  
**Cat. No.** : PC-23833  
**CAS No.** : 2724937-55-5  
**Molecular Formula** : C<sub>33</sub>H<sub>47</sub>N<sub>3</sub>O<sub>9</sub>  
**Molecular Weight** : 629.75  
**Target** : Other Targets  
**Solubility** : 10 mM in DMSO



CAS: 2724937-55-5

## Biological Activity

EOS301984 (EOS-984) is a potent, selective equilibrative nucleoside transporter 1 (**ENT1**) antagonist with IC<sub>50</sub> of 339.6 nM (human ENT1), 150-fold selectivity for ENT1 versus ENT2.

EOS301984 (EOS-984) displays little to no inhibitory activity against ENT4 or CNT1, CNT2 or CNT3.

EOS301984 (EOS-984) binds to human and mouse ENT1 with K<sub>d</sub> of 0.5 nM and 14.4 nM respectively.

EOS301984 (EOS-984) inhibited adenosine uptake into activated human T cells with sub-nanomolar potency and restored T cell proliferation both in the presence of adenosine and also dose-dependently in the presence of ATP acting as a source of adenosine.

EOS301984 (EOS-984) dose-dependently increased the levels of UMP, UDP, UTP and CTP in adenosine-treated T cells while also reducing adenosine-driven increases in carbamoyl aspartate, DHO and orotate.

EOS301984 (EOS-984) can restore T cell and tumor-infiltrating lymphocyte (TIL) expansion and effector function in high-adenosine environments.

EOS301984 (EOS-984) combined with anti-PD-1, can control tumor growth in a humanized mouse model of triple-negative breast cancer that is normally resistant to anti-PD-1 blockade.

## References

Patent WO2021204896 A1.

2. Theodore J Sanders, et al. *Nat Immunol*. 2025 May 12. doi: 10.1038/s41590-025-02153-3.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com